<p>K.J. Harrison &amp; Partners Inc 在第二季度根據其最近向證券交易委員會提交的 13F 表格購買了 Regeneron Pharmaceuticals, Inc.（NASDAQ:REGN - 免費報告）的新股份。這家機構投資者購買了 2,001 股這家生物製藥公司的股票，價值約為 1,051,000 美元。</p>
<ul>
<li>大熊星座：3 只接近一年低點的股票，可能在 2025 年大幅上漲</li>
</ul>
<p>其他幾家機構投資者和對沖基金也增加或減少了在 REGN 的持股。PGGM Investments 在第二季度將其在 Regeneron Pharmaceuticals 的股份增加了 159.7%。PGGM Investments 目前擁有 84,397 股這家生物製藥公司的股票，價值 4,430,800 美元，此前在上個季度購買了 51,900 股。Founders Capital Management LLC 在第二季度將其在 Regeneron Pharmaceuticals 的股份增加了 7.0%。Founders Capital Management LLC 目前擁有 8,274 股這家生物製藥公司的股票，價值 4,344,000 美元，此前在上個季度購買了 538 股。Sepio Capital LP 在第一季度將其在 Regeneron Pharmaceuticals 的股份增加了 33.1%。Sepio Capital LP 目前擁有 3,389 股這家生物製藥公司的股票，價值 2,150,000 美元，此前在上個季度購買了 842 股。China Universal Asset Management Co. Ltd.在第一季度將其在 Regeneron Pharmaceuticals 的股份增加了 3.9%。China Universal Asset Management Co. Ltd.目前擁有 25,629 股這家生物製藥公司的股票，價值 16,255,000 美元，此前在上個季度購買了 955 股。最後，Generate Investment Management Ltd 在第二季度獲得了 Regeneron Pharmaceuticals 的新頭寸，價值 6,300,000 美元。83.31% 的股票由機構投資者和對沖基金持有。</p>
<h2>Regeneron Pharmaceuticals 價格表現</h2>
<p>NASDAQ:REGN 週一開盤價為 651.80 美元。該公司的 50 日移動平均線為 581.80 美元，200 日移動平均線為 565.38 美元。該公司的市值為 690.8 億美元，市盈率為 15.61，PEG 比率為 2.03，貝塔值為 0.31。Regeneron Pharmaceuticals, Inc.的 52 周低點為 476.49 美元，52 周高點為 883.15 美元。該公司的債務與股本比率為 0.09，速動比率為 3.72，流動比率為 4.06。</p>
<ul>
<li>2025 年最佳生物科技股票</li>
</ul>
<p>Regeneron Pharmaceuticals（NASDAQ:REGN - 獲取免費報告）最近於 10 月 28 日星期二發佈了季度財報。這家生物製藥公司報告季度每股收益為 11.83 美元，超出分析師一致預期的 9.73 美元，超出幅度為 2.10 美元。該公司在本季度的收入為 37.5 億美元，而一致預期為 35.7 億美元。Regeneron Pharmaceuticals 的淨利潤率為 32.13%，股本回報率為 13.76%。該公司本季度的收入較去年同期增長了 0.9%。去年同期，該公司每股收益為 12.46 美元。整體來看，股票研究分析師預計 Regeneron Pharmaceuticals, Inc.在本財年的每股收益將達到 35.92 美元。</p>
<h2>Regeneron Pharmaceuticals 股息公告</h2>
<p>該公司最近宣佈了一項季度股息，將於 12 月 5 日星期五支付。11 月 20 日星期四的登記投資者將獲得每股 0.88 美元的股息。這代表着每年 3.52 美元的股息和 0.5% 的收益率。該股息的除息日期為 11 月 20 日星期四。Regeneron Pharmaceuticals 的股息支付比率（DPR）目前為 8.43%。</p>
<h2>分析師設定新目標價</h2>
<ul>
<li>3 只具有堅固資產負債表的股票，適合長期穩定投資</li>
</ul>
<p>REGN 已成為多份研究分析師報告的主題。Weiss Ratings 在 10 月 8 日星期三的研究報告中重申了對 Regeneron Pharmaceuticals 股票的 “持有（c-）” 評級。Cantor Fitzgerald 在 10 月 29 日星期三的研究報告中將 Regeneron Pharmaceuticals 的目標價從 678.00 美元上調至 740.00 美元，並給予該公司 “增持” 評級。Redburn Atlantic 在 8 月 14 日星期四的研究報告中將 Regeneron Pharmaceuticals 的股票評級上調至 “強烈買入”。Guggenheim 在 10 月 29 日星期三的報告中將 Regeneron Pharmaceuticals 的目標價從 815.00 美元上調至 865.00 美元，並給予該公司 “買入” 評級。最後，加拿大皇家銀行在 10 月 29 日星期三的報告中將 Regeneron Pharmaceuticals 的目標價從 704.00 美元上調至 708.00 美元，並給予該公司 “行業表現” 評級。三位股票研究分析師對該股給予了 “強烈買入” 評級，十六位給予了 “買入” 評級，七位給予了 “持有” 評級，一位給予了 “賣出” 評級。根據 MarketBeat 的數據，Regeneron Pharmaceuticals 目前的共識評級為 “適度買入”，平均目標價為 802.36 美元。</p>
<p><strong>查看我們關於 REGN 的最新研究報告</strong></p>
<h2>Regeneron Pharmaceuticals 的內部交易</h2>
<p>在相關消息中，董事 Christine A. Poon 在 10 月 29 日星期三的交易中出售了 6,500 股 Regeneron Pharmaceuticals 的股票。這些股票以 654.27 美元的平均價格出售，總交易額為 4,252,755.00 美元。交易完成後，該董事直接持有該公司 2,352 股股票，價值 1,538,843.04 美元。這筆交易代表着其持股比例減少了 73.43%。該出售在向 SEC 提交的文件中披露，文件可在此鏈接查看。7.02% 的股票由公司內部人士持有。</p>
<h2>關於 Regeneron Pharmaceuticals</h2>
<p>（免費報告）</p>
<p>再生元製藥公司發現、發明、開發、製造並商業化用於治療全球各種疾病的藥物。公司的產品包括用於治療濕性年齡相關性黃斑變性和糖尿病性黃斑水腫的 EYLEA 注射劑；近視性脈絡膜新生血管；糖尿病視網膜病；新生血管性青光眼；以及早產兒視網膜病。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過再生元製藥</li>
<li>最大的股票虧損者 - 今日最大百分比下跌者</li>
<li>適合任何市場的三隻安全穩健股票</li>
<li>什麼是支撐位？</li>
<li>Lemonade 股票在財報後是否會迎來大幅反彈？</li>
<li>什麼是 MarketRank™？如何使用它</li>
<li>卡特彼勒股票到年底可能超過 650 美元</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在再生元製藥嗎？</h2>
<p>在你考慮再生元製藥之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而再生元製藥並不在名單上。</p>
<p>雖然再生元製藥目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

再生元制藥

<p>K.J. Harrison & Partners Inc 在第二季度收購了再生元製藥的新股份，購買了 2,001 股，價值約為 105 萬美元。其他機構投資者也增加了他們的持股。再生元報告了強勁的季度收益，超出預期，每股收益為 11.83 美元，收入為 37.5 億美元。公司宣佈每股季度分紅為 0.88 美元，收益率為 0.5%。分析師對該股票的評級各異，目標價格範圍從 678 美元到 865 美元</p>

<p>K.J. Harrison &amp; Partners Inc bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The institutional investor bought 2,001 shares of the biopharmaceutical company's stock, valued at approximately $1,051,000.</p>
<div class="lb-trans"><p>K.J. Harrison &amp; Partners Inc 在第二季度根據其最近向證券交易委員會提交的 13F 表格購買了 Regeneron Pharmaceuticals, Inc.（NASDAQ:REGN - 免費報告）的新股份。這家機構投資者購買了 2,001 股這家生物製藥公司的股票，價值約為 1,051,000 美元。</p>
</div><ul>
<li>Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>大熊星座：3 只接近一年低點的股票，可能在 2025 年大幅上漲</li>
</ul>
</div><p>Several other institutional investors and hedge funds have also added to or reduced their stakes in REGN. PGGM Investments increased its stake in shares of Regeneron Pharmaceuticals by 159.7% during the 2nd quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company's stock worth $44,308,000 after purchasing an additional 51,900 shares during the last quarter. Founders Capital Management LLC grew its stake in Regeneron Pharmaceuticals by 7.0% in the 2nd quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company's stock valued at $4,344,000 after buying an additional 538 shares during the last quarter. Sepio Capital LP grew its stake in Regeneron Pharmaceuticals by 33.1% in the 1st quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company's stock valued at $2,150,000 after buying an additional 842 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Regeneron Pharmaceuticals by 3.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after buying an additional 955 shares during the last quarter. Finally, Generate Investment Management Ltd acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at $6,300,000. 83.31% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他幾家機構投資者和對沖基金也增加或減少了在 REGN 的持股。PGGM Investments 在第二季度將其在 Regeneron Pharmaceuticals 的股份增加了 159.7%。PGGM Investments 目前擁有 84,397 股這家生物製藥公司的股票，價值 4,430,800 美元，此前在上個季度購買了 51,900 股。Founders Capital Management LLC 在第二季度將其在 Regeneron Pharmaceuticals 的股份增加了 7.0%。Founders Capital Management LLC 目前擁有 8,274 股這家生物製藥公司的股票，價值 4,344,000 美元，此前在上個季度購買了 538 股。Sepio Capital LP 在第一季度將其在 Regeneron Pharmaceuticals 的股份增加了 33.1%。Sepio Capital LP 目前擁有 3,389 股這家生物製藥公司的股票，價值 2,150,000 美元，此前在上個季度購買了 842 股。China Universal Asset Management Co. Ltd.在第一季度將其在 Regeneron Pharmaceuticals 的股份增加了 3.9%。China Universal Asset Management Co. Ltd.目前擁有 25,629 股這家生物製藥公司的股票，價值 16,255,000 美元，此前在上個季度購買了 955 股。最後，Generate Investment Management Ltd 在第二季度獲得了 Regeneron Pharmaceuticals 的新頭寸，價值 6,300,000 美元。83.31% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Regeneron Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Regeneron Pharmaceuticals 價格表現</h2>
</div><p>NASDAQ:REGN opened at $651.80 on Monday. The company has a 50-day moving average of $581.80 and a 200-day moving average of $565.38. The company has a market capitalization of $69.08 billion, a price-to-earnings ratio of 15.61, a PEG ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $883.15. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.06.</p>
<div class="lb-trans"><p>NASDAQ:REGN 週一開盤價為 651.80 美元。該公司的 50 日移動平均線為 581.80 美元，200 日移動平均線為 565.38 美元。該公司的市值為 690.8 億美元，市盈率為 15.61，PEG 比率為 2.03，貝塔值為 0.31。Regeneron Pharmaceuticals, Inc.的 52 周低點為 476.49 美元，52 周高點為 883.15 美元。該公司的債務與股本比率為 0.09，速動比率為 3.72，流動比率為 4.06。</p>
</div><ul>
<li>Best Biotech Stocks to Buy in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年最佳生物科技股票</li>
</ul>
</div><p>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping analysts' consensus estimates of $9.73 by $2.10. The company had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm's revenue for the quarter was up .9% compared to the same quarter last year. During the same period last year, the firm earned $12.46 EPS. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Regeneron Pharmaceuticals（NASDAQ:REGN - 獲取免費報告）最近於 10 月 28 日星期二發佈了季度財報。這家生物製藥公司報告季度每股收益為 11.83 美元，超出分析師一致預期的 9.73 美元，超出幅度為 2.10 美元。該公司在本季度的收入為 37.5 億美元，而一致預期為 35.7 億美元。Regeneron Pharmaceuticals 的淨利潤率為 32.13%，股本回報率為 13.76%。該公司本季度的收入較去年同期增長了 0.9%。去年同期，該公司每股收益為 12.46 美元。整體來看，股票研究分析師預計 Regeneron Pharmaceuticals, Inc.在本財年的每股收益將達到 35.92 美元。</p>
</div><h2>Regeneron Pharmaceuticals Dividend Announcement</h2>
<div class="lb-trans"><h2>Regeneron Pharmaceuticals 股息公告</h2>
</div><p>The company also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Thursday, November 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.43%.</p>
<div class="lb-trans"><p>該公司最近宣佈了一項季度股息，將於 12 月 5 日星期五支付。11 月 20 日星期四的登記投資者將獲得每股 0.88 美元的股息。這代表着每年 3.52 美元的股息和 0.5% 的收益率。該股息的除息日期為 11 月 20 日星期四。Regeneron Pharmaceuticals 的股息支付比率（DPR）目前為 8.43%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><ul>
<li>3 Stocks With Ironclad Balance Sheets for Long-Term Stability</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只具有堅固資產負債表的股票，適合長期穩定投資</li>
</ul>
</div><p>REGN has been the topic of a number of research analyst reports. Weiss Ratings reiterated a &#34;hold (c-)&#34; rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 8th. Cantor Fitzgerald raised their target price on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an &#34;overweight&#34; rating in a research note on Wednesday, October 29th. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a &#34;strong-buy&#34; rating in a research note on Thursday, August 14th. Guggenheim increased their price target on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, October 29th. Finally, Royal Bank Of Canada increased their price target on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a &#34;sector perform&#34; rating in a report on Wednesday, October 29th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $802.36.</p>
<div class="lb-trans"><p>REGN 已成為多份研究分析師報告的主題。Weiss Ratings 在 10 月 8 日星期三的研究報告中重申了對 Regeneron Pharmaceuticals 股票的 “持有（c-）” 評級。Cantor Fitzgerald 在 10 月 29 日星期三的研究報告中將 Regeneron Pharmaceuticals 的目標價從 678.00 美元上調至 740.00 美元，並給予該公司 “增持” 評級。Redburn Atlantic 在 8 月 14 日星期四的研究報告中將 Regeneron Pharmaceuticals 的股票評級上調至 “強烈買入”。Guggenheim 在 10 月 29 日星期三的報告中將 Regeneron Pharmaceuticals 的目標價從 815.00 美元上調至 865.00 美元，並給予該公司 “買入” 評級。最後，加拿大皇家銀行在 10 月 29 日星期三的報告中將 Regeneron Pharmaceuticals 的目標價從 704.00 美元上調至 708.00 美元，並給予該公司 “行業表現” 評級。三位股票研究分析師對該股給予了 “強烈買入” 評級，十六位給予了 “買入” 評級，七位給予了 “持有” 評級，一位給予了 “賣出” 評級。根據 MarketBeat 的數據，Regeneron Pharmaceuticals 目前的共識評級為 “適度買入”，平均目標價為 802.36 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on REGN</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 REGN 的最新研究報告</strong></p>
</div><h2>Insider Transactions at Regeneron Pharmaceuticals</h2>
<div class="lb-trans"><h2>Regeneron Pharmaceuticals 的內部交易</h2>
</div><p>In related news, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares of the company's stock, valued at $1,538,843.04. This trade represents a 73.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.02% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相關消息中，董事 Christine A. Poon 在 10 月 29 日星期三的交易中出售了 6,500 股 Regeneron Pharmaceuticals 的股票。這些股票以 654.27 美元的平均價格出售，總交易額為 4,252,755.00 美元。交易完成後，該董事直接持有該公司 2,352 股股票，價值 1,538,843.04 美元。這筆交易代表着其持股比例減少了 73.43%。該出售在向 SEC 提交的文件中披露，文件可在此鏈接查看。7.02% 的股票由公司內部人士持有。</p>
</div><h2>About Regeneron Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Regeneron Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.</p>
<div class="lb-trans"><p>再生元製藥公司發現、發明、開發、製造並商業化用於治療全球各種疾病的藥物。公司的產品包括用於治療濕性年齡相關性黃斑變性和糖尿病性黃斑水腫的 EYLEA 注射劑；近視性脈絡膜新生血管；糖尿病視網膜病；新生血管性青光眼；以及早產兒視網膜病。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Regeneron Pharmaceuticals</li>
<li>Biggest Stock Losers - Today’s Biggest Percentage Decliners</li>
<li>3 Safe and Steady Stocks for Any Market</li>
<li>What is a support level?</li>
<li>Is Lemonade Stock Set for a Big Squeeze After Earnings?</li>
<li>What is MarketRank™? How to Use it</li>
<li>Caterpillar Stock Could Top $650 by Year’s End</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過再生元製藥</li>
<li>最大的股票虧損者 - 今日最大百分比下跌者</li>
<li>適合任何市場的三隻安全穩健股票</li>
<li>什麼是支撐位？</li>
<li>Lemonade 股票在財報後是否會迎來大幅反彈？</li>
<li>什麼是 MarketRank™？如何使用它</li>
<li>卡特彼勒股票到年底可能超過 650 美元</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=REGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在再生元製藥嗎？</h2>
</div><p>Before you consider Regeneron Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮再生元製藥之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而再生元製藥並不在名單上。</p>
</div><p>While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然再生元製藥目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

K.J. Harrison & Partners Inc 購入了再生元製藥公司（Regeneron Pharmaceuticals, Inc.）的新股票 $REGN